Potent synthetic hexapeptide growth hormone secretagogue. Investigated for GH axis stimulation and studied separately for cardiovascular receptor interactions in preclinical research.
Hexarelin is a research compound available through our china peptide catalog as a finished, lyophilized vial from an established Chinese manufacturer. It belongs to the Synthetic hexapeptide (GH secretagogue)
Research Areas
GH axis pharmacology, cardiac protection, ischemia-reperfusion research, dual-receptor pharmacology
Available Variants
| Name | Strength | Pack Size | Purity | Availability |
|---|---|---|---|---|
| Hexarelin | 5 mg | 10 vials | ≥98% | In Stock |
| Hexarelin | 5 mg | 10 vials | — | In Stock |
Specification Highlights
Quality & Testing
Testing method: HPLC / LC-MS . Products are supplied against the specification shown on the applicable product page. The standard catalog purity specification is ≥98% unless otherwise stated. Product-specific specifications and quality-control information may vary by compound and batch. Every batch is tested by the manufacturer for purity and concentration as part of routine quality control, using methods such as HPLC and LC-MS. These results are kept in the manufacturer’s internal quality-control records and are not issued as a separate certificate or document.
Variant Notes
Synthetic hexapeptide and agonist of the ghrelin receptor GHS-R1a. Investigated in the context of growth hormone secretion, neuroendocrine signalling, and interactions between ghrelin receptors and cellular processes.
Research Areas
GH Secretagogue Potency Studies Hexarelin is among the most potent GHS-R1a agonists in the hexapeptide GHRP family, producing high-amplitude GH pulses in rodent and primate models. Structure-activity research has examined how the 2-methyltryptophan modification affects receptor binding affinity, selectivity, and GH release amplitude compared to GHRP-6 (tryptophan at position 2) and GHRP-2 (2-naphthylalanine). Hexarelin’s potency profile makes it a useful upper-end reference in GHS-R1a pharmacological studies. Cardiac Protection Research (CD36 Pathway) A distinct research area for hexarelin involves cardioprotective activity that persists in hypophysectomized animals and in the presence of somatostatin — conditions that abolish pituitary GH release. This GH-independent activity has been traced to CD36, a scavenger receptor expressed in cardiac tissue. Studies in ischemia-reperfusion models have examined hexarelin’s effects on cardiomyocyte survival, infarct size reduction, and contractile recovery through this alternative receptor pathway. GH-Independent Receptor Mechanisms Hexarelin’s dual receptor engagement — GHS-R1a in the pituitary and CD36 in cardiac and vascular tissue — has generated research interest in separating its GH-dependent from GH-independent biological effects. Studies using hypophysectomy, GH antibody neutralization, and CD36-knockout models have been used to parse these distinct pharmacological contributions, making hexarelin a valuable tool for studying GH secretagogue biology beyond the pituitary. ## Sourcing Hexarelin From China
Hexarelin is available through our platform as a china peptide sourced directly from an established Chinese manufacturer. Three points define how we handle it:
- Factory-direct, not trader-sourced. We confirm availability and specification with the manufacturer before the order is confirmed. There is no intermediary resale of unknown-origin vials in this catalog.
- Specification before shipment. The purity and concentration specification shown on this page is the manufacturer’s batch specification. Product-specific quality-control information travels with the order.
- Research-use discipline. Like every listing in our catalog, Hexarelin is supplied for laboratory research use only, under strict research-use terms.
For buyers comparing chinese peptides suppliers, the practical test is whether the seller can name the manufacturer and show the batch documentation. We work the other way around: the manufacturer and the documentation are the offer. Browse the full catalog or see how sourcing works.
Available Variants
| Name | Strength | Pack Size | Purity | Availability |
|---|---|---|---|---|
| Hexarelin | 5 mg | 10 vials | ≥98% | In Stock |
| Hexarelin | 5 mg | 10 vials | — | In Stock |
Specification Highlights
Quality & Testing
Testing method: HPLC / LC-MS . Products are supplied against the specification shown on the applicable product page. The standard catalog purity specification is ≥98% unless otherwise stated. Product-specific specifications and quality-control information may vary by compound and batch. Every batch is tested by the manufacturer for purity and concentration as part of routine quality control, using methods such as HPLC and LC-MS. These results are kept in the manufacturer’s internal quality-control records and are not issued as a separate certificate or document.
Variant Notes
Synthetic hexapeptide and agonist of the ghrelin receptor GHS-R1a. Investigated in the context of growth hormone secretion, neuroendocrine signalling, and interactions between ghrelin receptors and cellular processes.
Research Areas
GH Secretagogue Potency Studies Hexarelin is among the most potent GHS-R1a agonists in the hexapeptide GHRP family, producing high-amplitude GH pulses in rodent and primate models. Structure-activity research has examined how the 2-methyltryptophan modification affects receptor binding affinity, selectivity, and GH release amplitude compared to GHRP-6 (tryptophan at position 2) and GHRP-2 (2-naphthylalanine). Hexarelin’s potency profile makes it a useful upper-end reference in GHS-R1a pharmacological studies. Cardiac Protection Research (CD36 Pathway) A distinct research area for hexarelin involves cardioprotective activity that persists in hypophysectomized animals and in the presence of somatostatin — conditions that abolish pituitary GH release. This GH-independent activity has been traced to CD36, a scavenger receptor expressed in cardiac tissue. Studies in ischemia-reperfusion models have examined hexarelin’s effects on cardiomyocyte survival, infarct size reduction, and contractile recovery through this alternative receptor pathway. GH-Independent Receptor Mechanisms Hexarelin’s dual receptor engagement — GHS-R1a in the pituitary and CD36 in cardiac and vascular tissue — has generated research interest in separating its GH-dependent from GH-independent biological effects. Studies using hypophysectomy, GH antibody neutralization, and CD36-knockout models have been used to parse these distinct pharmacological contributions, making hexarelin a valuable tool for studying GH secretagogue biology beyond the pituitary.
Compound Profile
Hexarelin (Examorelin) is a synthetic hexapeptide GH secretagogue and GHS-R1a agonist, structurally related to GHRP-6 but with a 2-methyl-tryptophan (α-methyltryptophan) at position 2 — a modification associated with the highest reported GH-releasing potency among the hexapeptide GHRP family. Beyond its pituitary effects, hexarelin is notable in research for cardiovascular activity mediated via CD36 (scavenger receptor B) and a distinct GHS-R1a-independent pathway, making it a pharmacologically complex research tool that spans GH axis and cardiac biology. Preclinical studies have documented hexarelin’s robust GH stimulation in rodent and primate models, generally exceeding the GH release amplitude achieved by GHRP-6 or GHRP-2 at equivalent doses. A separate line of research has examined hexarelin’s cardioprotective properties in ischemia-reperfusion injury models — an area of interest because the observed cardiac effects appear to persist even in somatostatin-suppressed or hypophysectomized animals, implicating a GH-independent receptor mechanism (CD36) in cardiac signaling. Peptides of China supplies hexarelin as a lyophilized powder at 99%+ purity, verified by HPLC and Mass Spectrometry. Every batch is tested by the manufacturer for purity and concentration as part of routine quality control. All products are for laboratory research use only and are not for human consumption.
Profile
Research Areas
GH axis pharmacology, cardiac protection, ischemia-reperfusion research, dual-receptor pharmacology
Available Variants
| Name | Strength | Pack Size | Purity | Availability |
|---|---|---|---|---|
| Hexarelin | 5 mg | 10 vials | ≥98% | In Stock |
| Hexarelin | 5 mg | 10 vials | — | In Stock |
Specification Highlights
Quality & Testing
Testing method: HPLC / LC-MS . Products are supplied against the specification shown on the applicable product page. The standard catalog purity specification is ≥98% unless otherwise stated. Product-specific specifications and quality-control information may vary by compound and batch. Every batch is tested by the manufacturer for purity and concentration as part of routine quality control, using methods such as HPLC and LC-MS. These results are kept in the manufacturer’s internal quality-control records and are not issued as a separate certificate or document.
Variant Notes
Synthetic hexapeptide and agonist of the ghrelin receptor GHS-R1a. Investigated in the context of growth hormone secretion, neuroendocrine signalling, and interactions between ghrelin receptors and cellular processes.
Research Areas
GH Secretagogue Potency Studies Hexarelin is among the most potent GHS-R1a agonists in the hexapeptide GHRP family, producing high-amplitude GH pulses in rodent and primate models. Structure-activity research has examined how the 2-methyltryptophan modification affects receptor binding affinity, selectivity, and GH release amplitude compared to GHRP-6 (tryptophan at position 2) and GHRP-2 (2-naphthylalanine). Hexarelin’s potency profile makes it a useful upper-end reference in GHS-R1a pharmacological studies. Cardiac Protection Research (CD36 Pathway) A distinct research area for hexarelin involves cardioprotective activity that persists in hypophysectomized animals and in the presence of somatostatin — conditions that abolish pituitary GH release. This GH-independent activity has been traced to CD36, a scavenger receptor expressed in cardiac tissue. Studies in ischemia-reperfusion models have examined hexarelin’s effects on cardiomyocyte survival, infarct size reduction, and contractile recovery through this alternative receptor pathway. GH-Independent Receptor Mechanisms Hexarelin’s dual receptor engagement — GHS-R1a in the pituitary and CD36 in cardiac and vascular tissue — has generated research interest in separating its GH-dependent from GH-independent biological effects. Studies using hypophysectomy, GH antibody neutralization, and CD36-knockout models have been used to parse these distinct pharmacological contributions, making hexarelin a valuable tool for studying GH secretagogue biology beyond the pituitary.